ABSTRACT
Hereditary paraganglioma (PGL) is characterised by genetic predisposition to the development of highly vascular tumours of the paraganglionic tissues and caused by germ line inactivating mutations in the SDHB, SDHC and SDHD subunits of mitochondrial succinate dehydrogenase enzyme complex (SDH; mitochondrial complex II). Recent studies have demonstrated that SDH gene mutations in germ line occur in at least 11% of non-familial head and neck paragangliomas, 8% of non-familial pheochromocytomas, 28% of malignant pheochromocytomas and 33% of extra-adrenal pheochromocytomas. An increasing amount of data suggest that PGL mutations lead to constitutive activation of hypoxia signalling pathways. Genetic and structural models suggest that SDH mutations cause an accumulation of succinate and reactive oxygen species (ROS) which might act as downstream signalling molecules that activate hypoxia inducible pathways. However, many fundamental aspects of PGL pathogenesis, including the mechanism of ROS accumulation, the imprinted transmission pattern of SDHD mutations, and the precise role of SDH in regulation of oxygen homeostasis, remain poorly understood.
Paragangliomas are rare tumours that derive from minute, diffuse paraganglionic tissues which are located internally and centrally around the major arteries, nerves, within organs and distributed from the skull base to the pelvic floor. The carotid body (CB), located at the bifurcation of common carotid arteries in the neck and adrenal medulla are the two major paraganglionic organs in the adult. Paraganglionic tissues play an important role in organismic homeostasis either by serving as direct oxygen or carbon dioxide sensors, as performed primarily by the CB, 1 or by secreting catecholamines following stress induced nerve stimulation, as performed primarily by the adrenal medulla. The organ of Zuckerkandl (OZ), the clusters of paraganglionic tissues around the origin of the inferior mesenteric artery from the aorta, is the major paraganglionic organ that secretes catecholamines in the fetal and newborn period. As the OZ regresses after infancy, the CB and adrenal medulla takes over as the major paraganglionic organ.
2 . Paraganglioma tumour formation is the major pathologic condition of the paraganglionic system. When a paraganglioma tumour is hormonally active, it is referred to as a pheochromocytoma. The yearly clinical incidences of paragangliomas and pheochromocytomas are estimated as 1/ 1 000 000 and 2/1 000 000, respectively.
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Hereditary paraganglioma (PGL) is characterised by the development of multiple, early onset and familial paragangliomas as a result of germ line mutations in the predisposing genes. The first paraganglioma gene was identified as the D subunit (SDHD) of heterotetrameric succinate dehydrogenase (SDH; mitochondrial complex II) enzyme complex after many years of gene mapping studies. 3 Subsequently, mutations were identified in the SDHC and SDHB subunits by direct candidate gene analyses. 4 5 The SDH mutations predisposing to PGL are heterozygous, transmitted in germ line and cause loss of function. The neoplastic transformation follows somatic loss of the normal non-mutated gene copy, thus defining the SDH subunits as classical tumour suppressor genes. Surprisingly, mutations in the major catalytical subunit SDHA have yet to be linked to PGL, although homozygous mutations in SDHA cause neurodegenerative disorders resembling other mitochondrial diseases. 6 
PREVALENCE OF SDH MUTATIONS IN PARAGANGLIOMA AND PHEOCHROMOCYTOMA
Translational studies performed after the discovery of PGL genes showed that SDH germ line mutations account for a significant fraction of unselected paraganglioma patients. When there is a family history of head and neck paragangliomas (HNPs), SDH mutations account for most of these cases. The proportion of HNPs with a positive family history ranges from 9.5-50% in various studies. 2 Among families with HNPs with or without the development of pheochromocytomas, SDHB, SDHC and SDHD mutations were found, respectively, in 20%, 10%, 50% of 10 families in the USA, 7 8 6%, 0% and 94% of 32 families in The Netherlands, 9 10 and 9%, 0% and 82% of 11 families in Australia. 11 Germ line mutation rates in non-familial HNPs are more variable across studies. In larger series where the three PGL genes were evaluated, SDHB, SDHC and SDHD mutations were found respectively in approximately 3%, 3% and 5% of 37 19 ; and 6% and 6% of 17 cases from Japan. 20 Importantly, SDHC mutations appear to be rare in PCs. 21 22 Taken together, these genetic studies suggest that 8-12.5% of non-syndromic, non-familial PCs are caused by occult germ line mutations in SDHB or SDHD. It is worth noting that these prevalence values may actually underestimate the true frequency of germ line SDH mutations in HNPs and pheochromocytomas since the large deletions that were identified in certain PGL families, 8 23 24 were not tested in any of the above listed mutation surveys.
PENETRANCE AND EXPRESSIVITY OF SDH MUTATIONS
Genotype-phenotype studies in SDH mutation carriers suggest several distinct features between PGLs caused by SDHB and SDHD mutations. Most significantly, SDHD mutations cause PGL only after a paternal transmission, whereas maternal transmission of the SDHD mutations does not cause tumours. This transmission pattern is most consistent with genomic imprinting and is observed only in SDHD among the PGL genes. Maternal transmission of PGL phenotype by an SDHD mutation was recently described in one family. 25 If this observation is further confirmed in additional members of this family or in other families, it might provide a unique opportunity to identify mutated regulatory elements important for imprinted transmission of SDHD mutations.
SDHB 16 17 and at least 28% of malignant PCs are caused by SDHB germ line mutations. 17 29 SDHC germ line mutations are characterised primarily by solitary HNPs and incomplete penetrance. 21 Despite differences in the initial presentations of SDHB and SDHD mutations, the lifetime penetrances of HNPs and PCs are similar among SDHB and SDHD mutation carriers. 26 27 PGL gene mutations were also implicated in predisposition to kidney tumours, 27 gastric sarcomas 31 and childhood T cell acute leukaemias. 32 Further studies are needed to confirm the significance of SDH gene mutations in these neoplasia.
ROLE OF ENVIRONMENT IN THE PENETRANCE OF PGL MUTATIONS
It is well known that the CB tumours can develop sporadically upon chronic hypoxic exposure as observed among high altitude dwellers. 33 Congruent with the environmental aetiology in HNPs among high altitude dwellers, recent genetic analysis of a small set of high altitude paragangliomas revealed no germ line SDH mutations. 34 In contrast, the predisposition to CB tumours and other HNPs in The Netherlands, one of the most populated human settlements in low altitudes in the world, 35 is genetically determined. More than 50% of unselected patients with HNPs in The Netherlands carry in their germ line one of the three Dutch SDHD founder mutations, D92Y, L95P, and L139P. 9 36 Notably, multiple PGL founder mutations that account for such a high fraction of unselected PGL cases have yet to be identified in any other population. One hypothesis that may explain this observation is that the prevalence of SDHD founder mutations in The Netherlands is a consequence of reduced penetrance of HNPs caused by low altitude dwelling (with associated high oxygen concentrations) which presumably lead to relaxation of natural selection on the SDHD mutations. 30 Low mortality and morbidity associated with HNPs in the reproductive period and the imprinted transmission of SDHD mutations probably also contribute to the founder effect.
PROGRESS IN UNDERSTANDING THE MECHANISMS OF TUMORIGENESIS IN PGL
Although the role of mitochondria has been implicated in carcinogenesis through the identification of many somatic mitochondrial DNA mutations, PGL is the first model linking heritable mitochondrial defects to cancer. 37 More recently, mutations in the fumarate hydratase protein (FH; fumarase), which hydrates fumarate to malate in the Krebs cycle, was also linked to an inherited tumour syndrome characterised by the development of leiomyomata of uterus and skin and renal cancer (HLRCC). 38 How mutations in these mitochondrial genes cause tumours is still not fully understood. However, it is now becoming clear that SDH and FH play a previously unrecognised and potentially important role in controlling cellular proliferation.
A role for SDH in oxygen sensing and signalling in the CB was originally suggested because loss of SDH by PGL gene mutations recapitulate the CB tumours that develop upon chronic hypoxic stimulation among high altitude dwellers. 3 The working hypothesis that posits a link between hypoxia sensing and the SDH complex has found support from several lines of research. The penetrance and the population genetics of SDHD mutations appears to be influenced by altitude. Specifically, living in higher altitudes increases the phenotypic severity and decreases the population frequency of SDHD mutations. 30 In explaining these results, the investigators suggest that the SDHD mutations may lead to an overactivation of hypoxia signalling pathways, which is exacerbated at high altitudes or suppressed at low altitudes. Moreover, it has been demonstrated that gene expression profiles of PCs caused by SDH mutations show robust upregulation of hypoxia inducible pathways, leading to virtually identical global gene expression patterns of PCs in PGL and VHL syndromes. 39 Despite the similarity between global gene expression patterns, there is also some evidence that certain genes can be differentially regulated between the PCs of PGL and VHL. 40 The PCs from NF1 and MEN 2 syndromes, however, show global gene expression profiles that are distinct from those of VHL and PGL. 39 Taken together, these findings suggest that the pathogeneses of PCs in PGL and VHL are similar and involve constitutive activation of hypoxia inducible pathways.
It has been established that the VHL protein serves as an adaptor between the hydroxylated HIF1-a protein and the ubiquitin protein degradation pathway. 41 The HIF1-a protein, the master transcriptional factor inducing hypoxia tolerance genes, is hydroxylated under normoxic conditions by a group of prolyl hydroxylase enzymes (PHDs) that use molecular oxygen, 2-oxoglutarate, iron and vitamin C. The constitutive activation of hypoxia inducible pathways in VHL is caused by the inability of mutant VHL protein to target hydroxylated HIF1-a protein for degradation, leading to constitutive activation of HIF1. It has been suggested that succinate accumulation inhibits the HIF1 PHDs leading to stabilisation of HIF1-a. 42 Similarly, inhibition of FH leads to an even greater degree of PHD inhibition and stabilisation of HIF1. 43 As a result of this process, HIF1-a and some of its transcriptional targets are upregulated both in PGL and HLRCC tumours. 44 Unlike paraganglioma, the leiomyoma is not a vascular tumour. Accordingly, global gene expression profiles of uterine leiomyomas from HLRCC show activation of glycolytic genes rather than the hypoxia/angiogenesis pathway that is observed in PGL tumours. 45 46 Recent data from a yeast paraganglioma model suggest that the accumulation of organic acids such as succinate may inhibit not only PHDs but other also other 2-oxoglutarate dependent enzymes, including Jlp1 which is involved in sulfur metabolism and histone demethylase Jhd1. 47 Thus, although inhibition of PHDs by succinate or fumarate alone may stabilise and activate certain hypoxia related genes, global gene expression profiles suggest that PGL and HLRCC tumours might develop through distinct mechanisms.
There is an accumulating body of evidence suggesting that genetic inhibition of SDH also increases reactive oxygen species (ROS) levels. These data are consistent with a model that ROS, or another short lived messenger molecule that accumulates upon SDH inactivation, signals the presence of hypoxia in the CB chemoreceptor cells under normal physiological conditions. ROS accumulation in SDH mutants was first suggested by a mev-1(kn1) mutant of Caenorhabditis elegans that harbours a homozygous inactivating missense Sdhc mutation and displays a premature aging phenotype as a result of increased superoxide levels. 48 Congruent with the worm model, hamster cell lines carrying heterozygous Sdhc mutations have been shown to have increased ROS production rates, 49 suggesting that inactivation of SDH complex increases ROS levels.
Constitutional loss-of-function mutations in SDH in mouse and yeast have also been associated with the production of increased ROS levels. Although the homozygous loss of the mouse Sdhd gene is incompatible with embryogenesis, the heterozygous mutant mouse survives and shows increased baseline activity in CB chemoreceptor cells, suggesting overactivation of acute hypoxia signalling mechanisms (presumably by increased production of ROS). 50 Deletion of sdha or sdhb 47 and point mutations in the sdhd gene 51 in yeast leads to increased production of ROS. However, the inhibition of human SDHA and SDHB in tissue culture by pharmacologic and RNA interference methods suggests that, whereas SDHB inhibition causes ROS increase and subsequent HIF1 activation, SDHA inhibition does not increase ROS levels. 52 Whether these contrasting observations regarding the consequences of SDHA gene loss have a biological or technical basis remains to be determined. In addition, inhibition of neuronal apoptosis has been suggested in the pathogenesis of PGL tumours. 53 This model, however, does not explain why hypoxia related genes are activated in PCs from PGL and VHL, but not in those from MEN2 and NF1, and why PGL tumours develop primarily in the third and fourth decades of life rather than in infancy and childhood, since a predominantly early age-of-onset would be expected if PGL tumours were caused by inhibition of developmental neuronal apoptosis.
SOME UNSOLVED PROBLEMS IN PGL
Despite rapid progress in establishing a fundamental role for SDH in paraganglioma and PC susceptibility, several outstanding questions on basic and clinical aspects of PGL remain unsolved:
What are the causes of penetrance and expressivity differences among the SDH subunits?
Genotype-phenotype association studies indicate that SDHD mutations are more likely to cause head and neck tumours, whereas SDHB mutations are more likely to cause non-head and neck tumours. Perhaps tissue specific expressional differences among the SDH subunit genes in head/neck versus non-head/ neck paraganglia could be responsible for such penetrance/ expressivity differences. It is also unclear why SDHB mutations are particularly prone to be malignant. If non-HNPs are biologically more likely to metastasise than the HNPs, then the association of SDHB mutations with malignancy could be an indirect consequence of association of SDHB mutations with non-head/neck paragangliomas.
What is the mechanism of parent-of-origin effect in PGL caused by SDHD mutations at chromosome band 11q23?
No experimental evidence exists yet to explain why maternal transmission of SDHD mutations rarely, if ever, causes PGL in the progeny. Recently, it has been suggested that the loss of a maternally expressed, unlinked gene on proximal chromosome 11 is necessary for tumour development in PGL. 54 According to this model, loss of this putatively imprinted gene and the normal SDHD gene copy occurs readily by a one-hit kinetics through whole maternal chromosome loss when the mutant gene is on the paternal chromosome. When the mutant SDHD gene is on the maternal chromosome 11, however, the loss of the normal paternal SDHD copy and the unlinked maternally expressed imprinted gene requires two independent somatic mutations (two hits), which is kinetically less favourable. This model fails to explain why PGL tumours develop so readily when SDHB or SDHC genes are mutated, since the development of tumours in these cases presumably also depends on ''two-hit kinetics'' here involving the independent loss of both normal gene copies on chromosome 1 and the putative maternally imprinted gene on chromosome 11. A paraganglia specific quantitative genomic imprinting model, in which the SDHD gene is normally suppressed in the paraganglionic tissues in a reversible fashion during female gametogenesis, may ultimately provide a more parsimonious explanation.
Recent description of an instance of maternal disease transmission by an SDHD mutation suggests that the maternal imprinting of SDHD gene may be disrupted in certain cases. 25 Nevertheless, the paternal only transmission of paragangliomas caused by SDHD mutations has been consistently observed in hundreds of families, suggesting an imprinting mechanism that suppresses the maternal SDHD allele. In fact, the occurrence of a different type of tissue specific suppression of SDH has been suggested by the recent discovery of SDHB gene downregulation by a recurrent inactivating stop-codon mutation (R46X) in normal peripheral blood cells. 32 Given the role of SDH in activation of hypoxia inducible pathways, it is conceivable that the genetic and epigenetic suppression of the SDH complex might occur in certain normal tissues to facilitate early detection of hypoxia.
Why are SDHA gene mutations not associated with PGL?
Recent data suggest that the human SDHA gene has a remarkable number of common polymorphisms in AfricanAmerican chromosomes consistent with long term balancing selection. 55 Notably, there is some evidence that mutations in SDHA lead to consequences similar to those found in PGL genes through ROS production 47 or succinate accumulation that leads to stabilisation of HIF1-a. 56 The absence of the PGL phenotype by SDHA mutations could be explained if expression of the SDHA gene is much higher than the PGL genes in the paraganglionic tissues and/or if the biochemical interaction between the SDHA and the PGL gene products during catalysis is fast and transient. If true, heterozygous mutations in SDHA would likely be insufficient to cause any functional SDH deficiency in the paraganglionic tissues. If, however, the expression of the SDHA gene relative to the PGL genes is low in certain non-paraganglionic tissues, functionally suboptimal SDHA alleles could reduce SDH activity which might lead to premature activation of hypoxia inducible pathways. Experimental genetic models where the SDHA gene is mutated could help to explicate the molecular consequences associated with the loss of SDHA.
What is the relative contribution of succinate versus ROS accumulation in hypoxic pathway activation and tumorigenesis in PGL?
It remains to be established whether succinate, ROS or both molecules are required for the activation of downstream hypoxia inducible pathways in PGL pathogenesis. As discussed previously, although both succinate and fumarate accumulation leads to stabilisation of HIF1-a by inactivating PHDs, HLRCC tumours do not show overactivation of hypoxia inducible pathways at the global gene expression and phenotypic levels. These results suggest that succinate inhibition of PHDs may not be sufficient to activate the hypoxia inducible pathways in PGL tumours. Instead, ROS or another messenger molecule that accumulates upon SDH inhibition either alone or in combination with succinate might be necessary for downstream hypoxic pathway activation. When compared with the slower acting PHD-HIF pathway, a role for a faster acting messenger molecule such as ROS is more consistent with the CB's physiological hypoxia response that is known to occur within seconds and is predicted to be constitutively activated by SDH mutations (fig 1) .
What is the mechanism of ROS accumulation when SDH is mutated?
Three dimensional structural models of prokaryotic and eukaryotic SDH enzymes are now available. 57 58 However, there is still uncertainty about precisely how the loss of SDH leads to increased ROS production. Since PGL gene products are completely lost during the process of tumorigenesis, it is unlikely that ROS is simply produced from SDH by a gain-offunction mechanism. One possibility is that SDHA gene products could be the source of electron leakage, if they remain stable after the loss of PGL gene products in PGL tumours. This model predicts that higher oxygen concentrations would promote PGL tumorigenesis by increasing the rate of electron leakage from the SDHA gene products. However, the data suggest the contrary: lower oxygen concentrations promote PGL tumorigenesis. 30 In addition, evidence from yeast deletion strains suggests that genetic loss of Sdha produces as much ROS as the loss of Sdhb. 47 Taken together, these results suggest that the SDH complex might have a currently unrecognised role in removal of ROS produced elsewhere in mitochondria. Perhaps ubisemiquinone radicals, in equilibrium with the ROS content in mitochondria, could be a substrate for SDH. In addition, the current role of heme, which is conserved in all known SDH enzymes, remains elusive. Recent data suggest a regulatory rather than a catalytical role for heme during oxidation of succinate to fumarate. 59 60 Because mutations at heme binding sites associate with PGL, 3 it is likely that the putative regulatory roles of heme must be critical for the overall SDH function. However, whether heme increases SDH catalytic rate by binding molecular oxygen or performs some other essential regulatory function remains to be investigated.
What is the exact role of SDH in oxygen sensing?
This is probably the most fundamental question prompted by the identification of hypoxia inducible pathway induction in PGL. Researchers have attributed hypoxic pathway activation in PGL to the accumulation of succinate or ROS. This accumulation is believed to result in aberrant regulation of protein complexes such as PHDs or other mitochondrial respiratory chain complexes that are thought to play a central role in oxygen sensing. 42 52 However, current data suggest that genetic mutations in PHDs or mitochondrial complexes other than SDH do not result in paragangliomas. 61 As such, it is possible that future studies will continue to challenge this conventional model and will confirm that SDH does not simply cause a Figure 1 Model for pathogenesis of hereditary paraganglioma. Both succinate and reactive oxygen species (ROS) accumulate in the mitochondria following mutations in the succinate dehydrogenase (SDH) subunit genes. These substrates presumably transit into the cytoplasm, constitutively stimulate acute and chronic hypoxia sensing and signalling pathways, and lead to paraganglioma formation. Acute hypoxia sensing occurs within seconds of oxygen deprivation and leads to stimulation of ventilation by an electrochemical mechanism. Chronic hypoxia sensing leads to a transcriptional response orchestrated by the hypoxia inducible factors (HIF).
deregulation of other oxygen sensors, but plays a major role in the mechanism of cellular oxygen sensing, at least in the paraganglionic tissues.
CONCLUSIONS
Genetic studies on rare paraganglioma families have dramatically influenced the clinical approach to paragangliomas and pheochromocytomas since the discovery of the first SDHD gene mutations in 2000. 3 The discovery of at-risk patient populations by gene testing has led to better patient management. Despite this rapid and important progress, many fundamental questions regarding the role of SDH in tumorigenesis remain to be answered. Continued growth in our understanding of questions pertaining to oxygen sensing and regulation of SDH have the potential to help develop rational therapies, not only for paragangliomas but also for other more common disorders promoted by aberrant hypoxic pathway activation.
